ArticleCancer research and treatment2023

Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea.

Hyun Gee Ryoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.